The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
- Study HIC#:2000033608
- Last Updated:08/06/2024
Are you experiencing suicidal thoughts but NOT planning to act on them? Have you tried antidepressants before without much success?
Help us understand the effects of the rapid antidepressant ketamine on the brain and earn up to $435 for your time.
For more information and to see if you are eligible to participate, contact 203-508-7787 or email nempro.lab@yale.edu.
Contact Us
For more information about this study, including how to volunteer, contact:
Nempro Lab
- Phone Number: 1-203-508-7787
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Trial Purpose and Description
The purpose of this study is to test the hypothesis that the anti-depressant and anti-suicidal effects of the N-methyl-D-aspartate receptor (NMDAR) antagonist ketamine are critically dependent on stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid receptors (AMPAR). We will use the NMDAR antagonist ketamine combined with the AMPAR antagonist perampanel to test this theory.
Eligibility Criteria
1. Be diagnosed with depression, bipolar disorder, and/or PTSD AND currently receiving treatment.
2. Be currently having thoughts of suicide but NOT intending to act on them
3. Be currently experiencing a depressive episode
4. Be willing to not use drugs, alcohol, or caffeine prior to receiving ketamine
